Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?

Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?

Background. The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. Methods. A literature search through the Medline database and Google was conducted. Articles publish...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of clinical psychiatry 2007, Vol.19 (2), p.133-143
Hauptverfasser: Motlová, Lucie, Španiel, Filip, Höschl, Cyril, Balon, Richard
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 143
container_issue 2
container_start_page 133
container_title Annals of clinical psychiatry
container_volume 19
creator Motlová, Lucie
Španiel, Filip
Höschl, Cyril
Balon, Richard
description Background. The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. Methods. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Results. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Conclusion. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.
doi_str_mv 10.3109/10401230701334606
format Article
fullrecord <record><control><sourceid>informahealthcare</sourceid><recordid>TN_cdi_informahealthcare_journals_10_3109_10401230701334606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_10401230701334606</sourcerecordid><originalsourceid>FETCH-informahealthcare_journals_10_3109_104012307013346063</originalsourceid><addsrcrecordid>eNqlj01OAzEMhSMEEuXnAOx8gYLTzA8VC1RBgTWd_cjKOCTVTFIlYTHcgFsTJMSGJRv7SX6fn54QVxKvlcT1jcQK5Uphi1KpqsHmSCxkXbVLpVb1cdHlviyG9lScpbRHxHVzWy_E5yYydJbL3PgZHp0xRXvNCZyHbBm2xjhNegaagn-DHevgB3hmz5GyC75w2R3SrG3ITv9iXWTKE_sMwcBOW_cRDrZ8dgRU-FceKfNQAlOIA8d0fyFODI2JL3_2ubh72nYPL0vnTYgTWaYxW02R-314j754eon9d_v-T3v1P_oL3rFnZg</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?</title><source>CLOCKSS</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Portico (Triggered Content) Journals</source><creator>Motlová, Lucie ; Španiel, Filip ; Höschl, Cyril ; Balon, Richard</creator><creatorcontrib>Motlová, Lucie ; Španiel, Filip ; Höschl, Cyril ; Balon, Richard</creatorcontrib><description>Background. The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. Methods. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Results. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Conclusion. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.</description><identifier>ISSN: 1040-1237</identifier><identifier>EISSN: 1547-3325</identifier><identifier>DOI: 10.3109/10401230701334606</identifier><language>eng</language><publisher>Informa UK Ltd</publisher><ispartof>Annals of clinical psychiatry, 2007, Vol.19 (2), p.133-143</ispartof><rights>2007 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids></links><search><creatorcontrib>Motlová, Lucie</creatorcontrib><creatorcontrib>Španiel, Filip</creatorcontrib><creatorcontrib>Höschl, Cyril</creatorcontrib><creatorcontrib>Balon, Richard</creatorcontrib><title>Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?</title><title>Annals of clinical psychiatry</title><description>Background. The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. Methods. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Results. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Conclusion. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.</description><issn>1040-1237</issn><issn>1547-3325</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqlj01OAzEMhSMEEuXnAOx8gYLTzA8VC1RBgTWd_cjKOCTVTFIlYTHcgFsTJMSGJRv7SX6fn54QVxKvlcT1jcQK5Uphi1KpqsHmSCxkXbVLpVb1cdHlviyG9lScpbRHxHVzWy_E5yYydJbL3PgZHp0xRXvNCZyHbBm2xjhNegaagn-DHevgB3hmz5GyC75w2R3SrG3ITv9iXWTKE_sMwcBOW_cRDrZ8dgRU-FceKfNQAlOIA8d0fyFODI2JL3_2ubh72nYPL0vnTYgTWaYxW02R-314j754eon9d_v-T3v1P_oL3rFnZg</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Motlová, Lucie</creator><creator>Španiel, Filip</creator><creator>Höschl, Cyril</creator><creator>Balon, Richard</creator><general>Informa UK Ltd</general><scope/></search><sort><creationdate>2007</creationdate><title>Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?</title><author>Motlová, Lucie ; Španiel, Filip ; Höschl, Cyril ; Balon, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-informahealthcare_journals_10_3109_104012307013346063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Motlová, Lucie</creatorcontrib><creatorcontrib>Španiel, Filip</creatorcontrib><creatorcontrib>Höschl, Cyril</creatorcontrib><creatorcontrib>Balon, Richard</creatorcontrib><jtitle>Annals of clinical psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Motlová, Lucie</au><au>Španiel, Filip</au><au>Höschl, Cyril</au><au>Balon, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?</atitle><jtitle>Annals of clinical psychiatry</jtitle><date>2007</date><risdate>2007</risdate><volume>19</volume><issue>2</issue><spage>133</spage><epage>143</epage><pages>133-143</pages><issn>1040-1237</issn><eissn>1547-3325</eissn><abstract>Background. The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders. Methods. A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included. Results. Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy. Conclusion. Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.</abstract><pub>Informa UK Ltd</pub><doi>10.3109/10401230701334606</doi></addata></record>
fulltext fulltext
identifier ISSN: 1040-1237
ispartof Annals of clinical psychiatry, 2007, Vol.19 (2), p.133-143
issn 1040-1237
1547-3325
language eng
recordid cdi_informahealthcare_journals_10_3109_10401230701334606
source CLOCKSS; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Portico (Triggered Content) Journals
title Are There Any Differences in the Efficacy among Second Generation Antipsychotics in the Treatment of Schizophrenia and Related Disorders?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T04%3A28%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20There%20Any%20Differences%20in%20the%20Efficacy%20among%20Second%20Generation%20Antipsychotics%20in%20the%20Treatment%20of%20Schizophrenia%20and%20Related%20Disorders?&rft.jtitle=Annals%20of%20clinical%20psychiatry&rft.au=Motlov%C3%A1,%20Lucie&rft.date=2007&rft.volume=19&rft.issue=2&rft.spage=133&rft.epage=143&rft.pages=133-143&rft.issn=1040-1237&rft.eissn=1547-3325&rft_id=info:doi/10.3109/10401230701334606&rft_dat=%3Cinformahealthcare%3E10_3109_10401230701334606%3C/informahealthcare%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true